Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 2 (1)
P 3 (1)

Trial Status

Recruiting2
Active Not Recruiting1
Withdrawn1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07281833Phase 3Recruiting

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

NCT04448886Phase 2Active Not Recruiting

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT06805812Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT04205786Not ApplicableWithdrawnPrimary

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

Showing all 4 trials

Research Network

Activity Timeline